BRCARE®

BRCARE®Series

 

# PART 1

 

 

 # Why do i need BRCARE test?

 

part1-1-1

 

  • The most common female cancer in Korea
  • Rapidly increased
  • 1st in women cancer
  • The incidence is decreasing in western countries
  • People with a BRCA mutation shows that their children, siblings, and parents have a 50% chance of possessing the same autosomal dominant mutation.

 

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

part1-2-1

 

  • BRCA1 and BRCA2 mutations are known to put women at high risk.
  • Hereditary Breast cancer accounts for 5-10% of all female breast cancer and this is caused by inherited mutations in BRCA 1 and BRCA 2.
  • Patients with a BRCA mutation have up to an 80% risk of developing breast cancer and up to 50% risk of developing ovarian cancer in their lifetime.
  • Primary breast cancer in the one breast has up to a 60% risk of developing breast cancer in the opposite breast as well.
  • Patients with a BRCA2 mutation have up to a 6% risk of developing male breast cancer.

 

# What is the BRCA gene(Breast Cancer Gene)

part1_3_1

 

  • BRCA genes: human genes that produce tumor suppressor proteins. These proteins help repair damaged DNA
    • BRCA1->located on chromosome 17
    • BRCA2 ->located on chromosome 13
  • Known genes causing inherited breast cancer
  • People with BRCA1, BRCA2 mutations show that their children have a 50% chance of possessing the same autosomal dominant mutation.

 

# The importance of RARE genes in hereditary breast/ovarian cancer

유전성 유방암에 관련된 유전자들

<유전성 유방암에 관련된 유전자들>

 

part1_4_2

(출처: Robinson et al., Management of an Inherited Predisposition to Breast Cancer, The New England Journal of Medicine / Antoniou et al., Breast-Cancer Risk in Families with Mutations in PALB2, The New England Journal of Medicine)

 

*If you do not have a family history, the risk of developing breast cancer is up to 33% in 70 years of age. If you do, the risk is up to 58% in 50 years of age.

 

 

 

# PART 2

 

What is the BRACARE® test?

  • BRCARE® tests for BRCA1/2 genes using parallel sequencing for accuracy that compares between bioinformatics analysis and pathogenicity mutation.
  • BRCARE® Plus tests rare genes mutation in TP53, PTEN, CDH1, and PALB2 for providing with precision analysis.

 

part2_2

 

  • 4 weeks to get result
  • High detection rate(99.9%)
  • Easily recognized report
  • High- quality reference data
  • Available with blood/saliva sample